Article: Early Stage Improvement

Jan Vertommen at Capsugel looks at enhancing the bioavailability of compounds for early stage clinical trials

Improving the bioavailability of orally administered waterinsoluble compounds is allowing pharma and biotech companies to generate more representative pharmacokinetic and safety data from their first-in-human trials. Improving the quality of data at this early stage could contribute to the success of the FDA’s Critical Path Initiative’s strategy of ‘failing faster’, helping to ensure that the safest and most effective drugs secure the resources required to reach the marketplace more quickly.